TrialCancer science2026

Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.

Jong-Seok Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.